Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors Journal Article


Authors: Verma, V.; Shostrom, V. K.; Kumar, S. S.; Zhen, W.; Hallemeier, C. L.; Braunstein, S. E.; Holland, J.; Harkenrider, M. M.; S Iskhanian, A.; Neboori, H. J.; Jabbour, S. K.; Attia, A.; Lee, P; Alite, F; Walker, J. M.; Stahl, J. M.; Wang, K; Bingham, B. S.; Hadzitheodorou, C.; Decker, R. H.; McGarry, R. C.; Simone, C. B., 2nd
Article Title: Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors
Abstract: BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early-stage non-small cell lung cancer (NSCLC) measuring /=5 cm is considerably less defined, with the existing literature limited to small, single-institution reports. The current multi-institutional study reported outcomes evaluating the largest such population reported to date. METHODS: Clinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring >/=5 cm without evidence of distant/lymph node metastasis who underwent SBRT using /=5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2016. (c) 2016 American Cancer Society.
Keywords: chemotherapy; Radiation Oncology; Non-small cell lung cancer; image-guided radiotherapy; stereotactic body radiotherapy; toxicity
Journal Title: Cancer
ISSN: 1097-0142; 0008-543X
Publisher: American Cancer Society  
Journal Place: United States
Date Published: 2016
Language: ENG
DOI/URL:
Notes: LR: 20161016; CI: (c) 2016; JID: 0374236; OTO: NOTNLM; 2016/08/01 [received]; 2016/08/31 [revised]; 2016/09/09 [accepted]; aheadofprint